- Home
- LTRN vs KYNB Comparison
LTRN vs KYNB Comparison
Compare LTRN & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTRN | KYNB |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 31.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LTRN | KYNB |
|---|---|---|
| Price | $2.56 | $7.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 46.6K | 30.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $7.11 |
| 52 Week High | $5.74 | $9.58 |
Technical Indicators
Market Signals| Indicator | LTRN | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 42.44 |
| Support Level | $2.53 | $7.37 |
| Resistance Level | $3.65 | $8.84 |
| Average True Range (ATR) | 0.20 | 0.60 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 19.23 | 26.86 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.